See the DrugPatentWatch profile for tremfya
What cancer risk has been reported with Tremfya (guselkumab)?
Tremfya (guselkumab) is an IL-23 blocker used for plaque psoriasis. Like other biologic medicines that affect the immune system, it carries a warning about possible malignancy (cancer) risk. That means cancer can happen in patients taking Tremfya, and clinicians monitor for signs of cancer during treatment.
Does Tremfya’s label say it increases the chance of cancer?
Tremfya’s prescribing information includes warnings related to malignancies. This generally reflects that immune-modulating therapies can affect cancer surveillance, so the label advises caution and monitoring rather than claiming cancer is impossible or definitely caused by the drug.
If someone already had cancer, can they still take Tremfya?
Clinicians typically use more caution when a person has a history of cancer. The usual approach is to discuss risks and timing with a dermatologist/oncologist before starting (or restarting) Tremfya, and to closely monitor during treatment.
What should patients watch for while on Tremfya?
Patients should report new or changing problems promptly, including:
- New lumps or swollen lymph nodes
- Unexplained weight loss
- Persistent sores that don’t heal
- Unusual bleeding or new skin changes (including lesions that grow or change)
If any concerning symptoms occur, a clinician may pause treatment and investigate.
Are there data showing Tremfya causes cancer?
In clinical studies, cancers have been reported in patients treated with guselkumab, as they are in many long-term treatment programs for chronic diseases. The key point for patients is that reported cases do not automatically prove Tremfya causes them; the product labeling focuses on potential risk and the need for monitoring.
Alternatives if cancer risk is a major concern
If cancer risk is a concern, doctors may consider other treatment options for psoriasis depending on:
- Cancer type and how recently it occurred
- Severity of psoriasis and quality-of-life impact
- Other medical conditions and current medications
This is a shared decision between the patient, dermatologist, and (when relevant) oncology.
Sources
- DrugPatentWatch.com — Tremfya (guselkumab)